Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: ASOS CEO Sells GBP20 Million In Shares

Fri, 30th Jan 2015 12:45

Director Dealings Summary - Week Ended January 30        
Company Name Position Buy or Sell Number of Shares Resulting Holding *Note
3i Group Caroline Banszky Non-Executive Director Buy 6,000 undisclosed Same day as dilluted net aset value increased 5%
ASOS Nick Robertson CEO Sold 744,600 7 million Deal worth GBP20 million
Braemar Shipping Jürgen Breuer Non-Executive Director Buy 6,000 6,000 First purchase
Brewin Dolphin Paul Wilson Director Buy 8,596 8,596  
Burberry Carolyn McCall Non-Executive Director Buy 1,117 undisclosed McCall also is CEO of easyJet
Bushveld Minerals Ian Watson Chairman Buy 540,000 undisclosed  
Crest Nicholson Steve Evans Production Director Sold 350,000 307,765 Same day as company reported profit increase
Daily Internet Michael Edelson Chairman Buy 6.3 million 27.6 million  
Daily Internet Christopher Evans CEO Buy 369,485 19.6 million  
Flybe Simon Laffin Chairman Buy 6,728 288,000 Same day as shares hit 14-month low
Foreign & Colonial Investment Trust  Christopher Keljik  Non-Executive Director Buy 9,000 72,001  
IG Group Stephen Hill Non-Executive Director Sold 42,000 79,324 Same day as Ex-dividend date
JPMorgan Smaller Cos Michael Quicke Chairman Buy 4.879 9,212  
JPMorgan Smaller Cos Andrew Robson Non-Executive Director Buy 1,000 2,163  
Learning Technologies Jonathan Satchell CEO Sold 3 million 110.2 million 11 days after saying  FY results to be ahead of expectations
Learning Technologies Leslie-Ann Reed Non-Executive Director Buy 750,000 750,000  
Learning Technologies Neil Elton Non-Executive Director Buy 160,000 160,000  
Kingfisher Ian Cheshire Director Sold 16,000 undisclosed Stood down as CEO on December, 8 2014
Kingfisher Kate Cheshire Spouse Sold 15,000 undisclosed  
Miton Group Gervais Williams MD Buy 295,000 9.1 million  
Porvair Raj Rajagopal Non-Executive Director Buy 15,000 15,000  
Proactis Sean McDonough COO Sold 100,000 121,666 Sold to other directors
Proactis Alan Aubrey Chairman Buy 25,000 1.1 million  
Proactis Rod Jones CEO Buy 25,000 1.9 million  
Proactis Tim Sykes CFO Buy 25,000 148,001  
Proactis Rodney Potts Non-Executive Director Buy 25,000 8.9 million  
ReNeuron Olav Hellebø CEO Buy 322,778 322,778  
ReNeuron Michael Hunt CFO Buy 161,556 1.5 million  
Telecom Plus Charles Wigoder Chairman Buy 25,000 16 million  
Telecom Plus Julian Schild Non-Executive Director Buy 25,000 158,682  
Telecom Plus Melvin Lawson Non-Executive Director Buy 25,000 2.1 million  
WYG Graham Olver COO Sold 23,404 1.9 million share options 2 days after WYG launched review into selling the company
WYG Louise Olver Spouse Sold 64,322 Nil  
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event.
When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam    
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
23 Nov 2021 16:02

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Nov 2021 12:20

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

Read more
26 Oct 2021 19:06

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Read more
26 Oct 2021 14:02

ReNeuron enters cancer therapy collaboration with UCL

(Sharecast News) - Cell-based therapeutic specialist ReNeuron has entered a collaboration agreement with University College London (UCL), it announced on Tuesday, to conduct research into the generation of immune cells from induced pluripotent stem cells (iPSCs), for anti-cancer cell therapies.

Read more
21 Oct 2021 16:40

Director dealings: Reneuron Group non-executive makes share purchase

(Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.

Read more
21 Oct 2021 14:07

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

Read more
18 Oct 2021 15:12

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Read more
18 Oct 2021 09:14

ReNeuron treats first Oxford patient as part of expanded study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.

Read more
11 Oct 2021 11:51

ReNeuron upbeat on positive data from Spain collaboration

(Sharecast News) - Exosome therapeutics developer ReNeuron announced positive data on Monday that it said provided "clear preclinical proof-of-concept" that its novel exosome drug delivery technology could effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

Read more
11 Oct 2021 11:05

IN BRIEF: ReNeuron gets positive results from exosome drug data

IN BRIEF: ReNeuron gets positive results from exosome drug data

Read more
11 Oct 2021 10:59

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Read more
1 Oct 2021 11:15

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

Read more
1 Oct 2021 10:33

ReNeuron gets approval to restart RP clinical study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa on Friday, confirming that it had received regulatory approval to restart the study in all geographies.

Read more
9 Sep 2021 16:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
6 Aug 2021 10:55

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.